— Kevin Dallas, a longtime Seattle-area tech and finance executive, was named CEO and board member of Bedford, Mass.-based enterprise software company EnterpriseDB (EDB). Dallas spent almost 25 years at… Read More
Athira Pharma’s stock plummeted nearly 70% Wednesday after a clinical trial testing its candidate drug for Alzheimer’s disease failed to meet its primary endpoint. The phase 2 trial enrolled 77… Read More
Here’s a rundown of the top life sciences and health news across the Pacific Northwest this week. Seagen CEO resigns after domestic violence arrest: Clay Siegall resigned as CEO and… Read More
The activist shareholder behind an attempt to replace the CEO of Athira Pharma has suspended his campaign. Billionaire Richard (Ric) Kayne nominated himself and an associate to the board in… Read More
The former head of clinical development and research at Athira Pharma criticized the company’s handling of an investigation that led to the resignation of longtime CEO Leen Kawas in October.… Read More
This week we highlighted the finalists for Health Innovation of the Year at the GeekWire Awards. The finalists showcase the strength of science and innovation in the Pacific Northwest. That… Read More
A billionaire investor of Athira Pharma is calling for the ouster of the Seattle company’s CEO and nominated himself and the former chief financial officer at Novartis for the board… Read More
— Lance Baldo stepped down as chief medical officer of Adaptive Biotechnologies. Baldo is “moving on to pursue another professional opportunity in the early cancer screening market close to home,”… Read More
Leen Kawas, the Seattle biotech exec who resigned as CEO of Athira Pharma after an investigation found she had altered doctoral research images that helped to form the initial basis… Read More
The former CEO of Athira Pharma wrote a letter of contrition addressed to employees on Thursday, after resigning in the wake of a company investigation concluding she had altered images… Read More
Leen Kawas has formally resigned as CEO and president of Athira Pharma and is stepping off the board after an investigation found the biotech executive altered images in scientific papers… Read More
— Law enforcement technology company Axon added former HTC Vive exec Chris Chin as vice president of immersive tech. In his new role, Chin will be responsible for Axon’s virtual… Read More
Athira Pharma is advancing its clinical trials in the wake of allegations of image manipulation in papers authored by its CEO, the company reported today in its second quarter financial… Read More
— Amy Nelson is getting back into co-working. The founder and former CEO of The Riveter announced Tuesday that she is the president of SaksWorks, a new partnership between Saks… Read More
The lawsuits have begun. Barely a week after the CEO of Athira Pharma was placed on temporary leave after allegations of altered images in scientific papers she authored, three class… Read More
Athira Pharma CEO Leen Kawas has been placed on temporary leave until the Seattle area biotechnology company completes a review “stemming from doctoral research Dr. Kawas conducted while at Washington… Read More
The approval on Monday of the first new drug for Alzheimer’s disease in nearly two decades — Biogen’s aducanumab — helps shine a light on a path forward for other… Read More
In a year when large swaths of the economy sputtered due to the pandemic, Wall Street opened its doors to new entrants with 218 companies raising $78 billion through initial… Read More
An “incredibly dynamic year of change,” a “new hope,” and a “gangbusters” year in which the tech sector will come “roaring back.” Those are some of the phrases used by… Read More
Seattle-based biotech company Athira Pharma announced a three-year grant totaling $15 million from the National Institute on Aging to support an upcoming clinical trial of a treatment that seeks to… Read More
More than 5 million Americans have Alzheimer’s disease, and the number is projected to rise to nearly 14 million by 2050. The disease is the sixth-leading cause of death in… Read More
Athira Pharma will raise at least $204 million as the Seattle biotech startup becomes a public company on Friday. Athira priced its IPO on Thursday evening at $17 per share,… Read More
Athira Pharma plans to price its stock at $15 to $17 per share and raise up to $170 million in its initial public offering. The Seattle biotech filed updated IPO… Read More
Here’s what we’re talking about on the GeekWire Podcast this week. When Athira Pharma filed with the Nasdaq for a possible initial public offering, led by CEO Leen Kawas, it… Read More
Leen Kawas is truly a unicorn. The 35-year-old co-founder and CEO of Seattle biotechnology company Athira Pharma would be the first woman to guide a company to an initial public… Read More
Athira Pharma is aiming to go public. The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for… Read More
The foundation of Athira Pharma began while Leen Kawas was earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago. Fast forward to today and the Seattle… Read More
Editor’s note: The GeekWire Awards are now virtual on July 23. Watch live below. Technology is increasingly influencing the science of health, and the delivery of health care. Scientists and… Read More
— T-Mobile‘s head of home and entertainment, Jeffrey Binder, has left the company. Binder was the CEO of television technology company Layer3 TV, which was acquired by T-Mobile in 2018.… Read More
Proteins, algorithms and apps — oh my! Health innovators across the Pacific Northwest continue to embrace technologies that go well beyond traditional drugs. The finalists for the Health Innovation of… Read More